EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in multi-omics for esophageal squamous cell carcinoma: diagnostic, prognostic, and therapeutic perspectives

Dengyun Zhao, Xinyu He, Yaping Guo iD, Huifang Wei, Zigang Dong iD, Kangdong Liu

Protein & Cell · 2026

DOI: 10.1093/procel/pwag005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Protein & Cell, 2026. Verfasst von Dengyun Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Center, Chest Hospital of Zhengzhou University, Zhengzhou 450000, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 280 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Central Plains Science and Technology Innovation Leading Talents, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal squamous cell carcinoma (ESCC) remains a major health burden, particularly in Asia, with poor patient prognosis despite advancements in radiotherapy, chemotherapy, and immunotherapy. The marked interpatient and intratumor heterogeneity of ESCC underscores the need for molecularly informed diagnostic and therapeutic strategies. Recent high-throughput omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, have substantially advanced our understanding of ESCC biology. Genomic profiling has revealed recurrent alterations such as TP53 and NOTCH1 mutations, as well as actionable targets including PIK3CA, FGFR1, and SOX2 amplifications, which provide new opportunities for precision therapy. Epigenomic and transcriptomic analyses have identified methylation-based early detection markers (e.g., PAX9, SIM2) and immune-related transcriptomic subtypes associated with prognosis and immunotherapy responsiveness. Proteomic and metabolomic studies have further uncovered cell cycle and spliceosome pathway activation and altered lactate metabolism, offering additional biomarker and therapeutic insights. In this review, we synthesize these multi-omics advances and highlight how they collectively inform improved diagnostic, prognostic, and therapeutic strategies for ESCC. Despite these developments, the clinical translation of multi-omics findings remains limited due to the lack of standardized analytical pipelines, insufficient multicenter validation, and the high cost and technical complexity of integrating multi-omics data into routine clinical workflows. Future research integrating artificial intelligence with multi-omics data holds promise for enhancing diagnostic accuracy and enabling more precise therapeutic decision-making in ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsHumansMultiomicsPrognosisBiomarkers, TumorMetabolomicsProteomicsGenomics

Stichwörter der Autor:innen

ESCCdiagnosis markerhigh-throughput omicsmechanismprognosis markertherapeutic targettumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Medical Research Center, Chest Hospital of Zhengzhou University, Zhengzhou 450000, China.
  • Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, China.
  • China-US (Henan) Hormel Cancer Institute, Zhengzhou 450000, China.
  • Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou 450000, China.
  • The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou 450000, China.
  • State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou 450000, China.

ORCID-Profile: Yaping Guo, Zigang Dong

Förderung

  • National Natural Science Foundation of China
  • Central Plains Science and Technology Innovation Leading Talents
  • China Postdoctoral Science Foundation

Zitieren

APA

Zhao, D., He, X., Guo, Y., Wei, H., Dong, Z., & Liu, K. (2026). Advances in multi-omics for esophageal squamous cell carcinoma: diagnostic, prognostic, and therapeutic perspectives. Protein & Cell. https://doi.org/10.1093/procel/pwag005

Vancouver

Zhao D, He X, Guo Y, Wei H, Dong Z, Liu K. Advances in multi-omics for esophageal squamous cell carcinoma: diagnostic, prognostic, and therapeutic perspectives. Protein & Cell. 2026. doi:10.1093/procel/pwag005

BibTeX
@article{Zhao2026,
  author = {Zhao, Dengyun and He, Xinyu and Guo, Yaping and Wei, Huifang and Dong, Zigang and Liu, Kangdong},
  title = {Advances in multi-omics for esophageal squamous cell carcinoma: diagnostic, prognostic, and therapeutic perspectives},
  journal = {Protein & Cell},
  year = {2026},
  doi = {10.1093/procel/pwag005}
}
Kostenlos starten →